Quick Answer
Rapport Therapeutics, Inc. reported R&D Expense of $94.79 million for fiscal year 2025.
Rapport Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $94.79M | +55.6% |
| 2024 | $60.94M | +117.6% |
| 2023 | $28.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.28M | +43.3% | -1.8% |
| June 30, 2025 | $22.68M | +44.6% | +15.9% |
| March 31, 2025 | $19.57M | +56.5% | +25.9% |
| September 30, 2024 | $15.54M | +105.1% | -0.9% |
| June 30, 2024 | $15.69M | +232.3% | +25.5% |
| March 31, 2024 | $12.50M | — | +65.0% |
| September 30, 2023 | $7.58M | — | +60.6% |
| June 30, 2023 | $4.72M | — | — |
- Rapport Therapeutics, Inc. showed an increase of +55.6% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Rapport Therapeutics, Inc.’s r&d expense has grown by 238.5% (from $28.00 million to $94.79 million).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: